Sarepta Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.0M | $701.9M | $540.1M | $380.8M | $301.0M |
| Cost of Revenue | $25.5M | — | — | — | — | — | — | — |
| Gross Profit | $2.17B | — | — | — | — | — | — | — |
| Gross Margin | 98.8% | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | $401.8M |
| SG&A Expense | $491.7M | $557.9M | $481.9M | $451.4M | $282.7M | $317.9M | $284.8M | $207.8M |
| Operating Income | $-699.8M | $218.1M | $-267.8M | $-536.2M | $-459.7M | $-564.2M | $-705.6M | $-343.6M |
| Operating Margin | -31.8% | 11.5% | -21.5% | -57.5% | -65.5% | -104.5% | -185.3% | -114.1% |
| Interest Expense | $-38.1M | $-18.4M | $-22.0M | $-53.2M | $63.5M | $59.9M | $30.7M | $33.7M |
| Pretax Income | $-702.2M | $260.8M | $-520.1M | $-690.0M | $-418.9M | $-553.1M | $-713.9M | $-362.6M |
| Income Tax Expense | $11.2M | $25.5M | $15.9M | $13.5M | $-168.0K | $1.1M | $1.2M | $-692.0K |
| Net Income | $-713.4M | $235.2M | $-536.0M | $-703.5M | $-418.8M | $-554.1M | $-715.1M | $-361.9M |
| Net Margin | -32.5% | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% | -187.8% | -120.2% |
| EPS (Basic) | $-7.13 | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-9.71 | $-5.46 |
| EPS (Diluted) | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-9.71 | $-5.46 |
| Shares Outstanding (Basic) | 100.1M | 95.1M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.3M |
| Shares Outstanding (Diluted) | 100.1M | 107.9M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |